Cargando…
Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches
BACKGROUND: Inhibition of mitogen-activated protein kinase (MEK, also known as MAPK2, MAPKK), a key molecule of the Ras/MAPK (mitogen-activated protein kinase) pathway, has shown promising effects on B-raf-mutated and some RAS (rat sarcoma)-activated tumors in clinical trials. The objective of this...
Autores principales: | Tegnebratt, Tetyana, Ruge, Elisabeth, Bader, Sabine, Ishii, Nobuya, Aida, Satoshi, Yoshimura, Yasushi, Ooi, Chia-Huey, Lu, Li, Mitsios, Nicholas, Meresse, Valerie, Mulder, Jan, Pawlak, Michael, Venturi, Miro, Tessier, Jean, Stone-Elander, Sharon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452660/ https://www.ncbi.nlm.nih.gov/pubmed/26116108 http://dx.doi.org/10.1186/s13550-014-0034-6 |
Ejemplares similares
-
[(18) F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models
por: Tegnebratt, Tetyana, et al.
Publicado: (2013) -
Visualization of angiogenesis during cancer development in the polyoma middle T breast cancer model: molecular imaging with (R)-[(11)C]PAQ
por: Samén, Erik, et al.
Publicado: (2014) -
[(68)Ga]ABY-028: an albumin-binding domain (ABD) protein-based imaging tracer for positron emission tomography (PET) studies of altered vascular permeability and predictions of albumin-drug conjugate transport
por: Jussing, Emma, et al.
Publicado: (2020) -
From ZeRO to HeRO: Saving lives one HeRO at a time
por: Ratcliff, Dr. Charlotte, et al.
Publicado: (2016) -
The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
por: Wada, Makoto, et al.
Publicado: (2014)